Comparative Pharmacology
Head-to-head clinical analysis: ALEVE D SINUS COLD versus TOLECTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE D SINUS COLD versus TOLECTIN.
ALEVE-D SINUS & COLD vs TOLECTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Naproxen 220 mg (as naproxen sodium) and pseudoephedrine HCl 120 mg orally every 12 hours; maximum 2 doses per 24 hours.
400-600 mg orally three times daily; maximum 1.8 g/day.
None Documented
None Documented
Naproxen: 12-17 hours (clinical: twice daily dosing); pseudoephedrine: 4-6 hours (clinical: every 4-6 hours).
Terminal half-life approximately 5-6 hours; clinical context: dosing every 6-8 hours required due to relatively short half-life; steady-state achieved within 24-30 hours.
Renal elimination: naproxen ~95% (mostly as unconjugated naproxen and 6-O-desmethyl naproxen), pseudoephedrine ~70-90% unchanged. Biliary/fecal: minor (<5% for each).
Renal (90-95% as unchanged drug and metabolites, primarily glucuronide conjugates); biliary/fecal (minor, <5%).
Category C
Category C
NSAID/Decongestant Combination
NSAID